diflucan 2mg ml infusion - search results

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

diflucan 200 mg/100ml

مستودع خوري - khoury drug store - fluconazole 200 mg/100ml - 200 mg/100ml

Namibia - English - Namibia Medicines Regulatory Council

diflucan iv (100ml)

pfizer laboratories (pty) ltd - fluconazole 2mg - solution for infusion - each 1ml of solution for infusion contains fluconazole 2mg

New Zealand - English - Medsafe (Medicines Safety Authority)

diflucan one

jntl consumer health (new zealand) limited - fluconazole 150mg; - capsule - 150 mg - active: fluconazole 150mg excipient: colloidal silicon dioxide gelatin lactose monohydrate magnesium stearate maize starch patent blue v tekprint black sw-9008 titanium dioxide - vaginal candidiasis.

United States - English - NLM (National Library of Medicine)

diflucan- fluconazole tablet diflucan- fluconazole powder, for suspension

roerig - fluconazole (unii: 8vzv102jfy) (fluconazole - unii:8vzv102jfy) - diflucan (fluconazole) is indicated for the treatment of: diflucan is also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly. diflucan (fluconazole) is contraindicated in patients who have shown hypersensitivity to fluconazole or to any of its excipients. there is no information regarding cross-hypersensitivity between fluconazole and other azole antifungal agents. caution should be used in prescribing diflucan to patients with hypersensitivity to other azoles. coadministration of other drugs known to prolong the qt interval and which are metabolized via the enzyme cyp3a4 such as erythromycin, pimozide, and quinidine are contraindicated in patients receiving fluconazole. (see clinical pharmacology: drug interaction studies and precautions .)

Israel - English - Ministry of Health

diflucan 50 mg5 ml

pfizer pfe pharmaceuticals israel ltd - fluconazole - powder for suspension - fluconazole 50 mg / 5 ml - fluconazole - fluconazole - fluconazole is indicated in the following fungal infections.fluconazole is indicated in adults for the treatment of:• cryptococcal meningitis.• coccidioidomycosis.• invasive candidiasis.• mucosal candidiasis including oropharyngeal, oesophageal candidiasis, candiduria and chronic mucocutaneous candidiasis.• chronic oral atrophic candidiasis (denture sore mouth) if dental hygiene or topical treatment are insufficient.• vaginal candidiasis, acute or recurrent; when local therapy is not appropriate.• candidal balanitis when local therapy is not appropriate.• dermatomycosis including tinea pedis, tinea corporis, tinea cruris, tinea versicolor and dermal candida infections when systemic therapy is indicated.• tinea unguinium (onychomycosis) when other agents are not considered appropriate.fluconazole is indicated in adults for the prophylaxis of:• relapse of cryptococcal meningitis in patients with high risk of recurrence.• relapse of oropharyngeal or oesophageal candidiasis in patients infected with hiv who are at high risk of experiencing relapse.• to reduce the incidence of recurrent vaginal candidiasis (4 or more episodes a year).• prophylaxis of candidal infections in patients with prolonged neutropenia (such as patients with haematological malignancies receiving chemotherapy or patients receiving hematopoietic stem cell transplantation).fluconazole is indicated in term newborn infants, infants, toddlers, children, and adolescents aged from 0 to 17 years old:fluconazole is used for the treatment of mucosal candidiasis (oropharyngeal, oesophageal), invasive candidiasis, cryptococcal meningitis and the prophylaxis of candidal infections in immunocompromised patients. fluconazole can be used as maintenance therapy to prevent relapse of cryptococcal meningitis in children with high risk of reoccurrence. therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti infective therapy should be adjusted accordingly.consideration should be given to official guidance on the appropriate use of antifungals.